Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that its four abstracts selected for presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting are now available on ASCO's official website.

These abstracts report on the company's three lead drug candidates, including olverembatinib (HQP1351), the first and only China-approved third-generation BCR-ABL inhibitor; lisaftoclax (APG-2575), a BCL-2 selective inhibitor; and APG-2449, a FAK/ALK/ROS1 inhibitor.

Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting taking place on May 31 - June 4, 2024 in Chicago, IL. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community.

"It is our pleasure to present the latest data on our key drug candidates at the ASCO Annual Meeting for the seventh consecutive year," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "These encouraging results once again highlight Ascentage Pharma's robust capabilities in global innovation and clinical development. Going forward, we will further expedite our clinical development programs globally in the hope of benefitting more patients in China and around the world as soon as possible."